Le Lézard
Classified in: Science and technology, Business
Subjects: EARNINGS, Conference Call, Webcast, Advisory

Intellicheck to Announce Fourth Quarter and Full Year 2019 Financial Results


Intellicheck (Nasdaq: IDN), an industry leader in identification authentication solutions, will report financial results on March 11, 2020 for the fourth quarter and full year ended December 31, 2019.

The Company will hold an earnings conference call on March 11 at 4:30 p.m. ET/1:30 p.m. PT to discuss operating results. To listen to the earnings conference call, please dial 877-407-8037. For callers outside the U.S., please dial 201-689-8037.

A replay of the conference call will be available shortly after completion of the live event. To listen to the replay, please dial 877-660-6853 and use conference identification number 13699516. For callers outside the U.S., please dial 201-612-7415 and use conference identification number 13699516. The replay will be available beginning approximately two hours after the completion of the live event and will remain available until March 26, 2020.

About Intellicheck

Intellicheck (Nasdaq: IDN) is a trusted industry leader in technology solutions that stop identity theft and fraud with real-time identification authentication and age verification. We make it possible for our clients to increase revenues, improve customer service, and increase operational efficiencies. The company is focused on partnering with banks, credit card issuers and retailers to prevent fraud. Intellicheck also serves law enforcement agencies, national defense clients and diverse state and federal government agencies. For more information on Intellicheck, visit http://www.intellicheck.com/ and follow Intellicheck on Twitter, on Facebook, on LinkedIn and on YouTube.


These press releases may also interest you

at 07:12
CalAmp , a global technology solutions pioneer transforming the mobile connected economy, today announced that it amended its existing $50 million credit facility with J.P. Morgan originally entered into on March 30, 2018. The new amendment extends...

at 07:10
The Dapagliflozin And Prevention of Adverse outcomes in Chronic Kidney Disease (DAPA-CKD) Phase III trial for FARXIGA (dapagliflozin) in patients with chronic kidney disease (CKD) will be stopped early following a recommendation from an independent...

at 07:10
IMV Inc. , a clinical-stage biopharmaceutical company (the "Company" or "IMV"), today provided updates on the development of DPX-COVID-19, a vaccine candidate against the novel coronavirus, and on the Company's business and clinical operations amid...

at 07:05
LifeMax Laboratories, Inc. ("LifeMax"), a private company focused on treating orphan diseases that have few or no therapeutic options, today announced the formation of AmMax Bio, Inc. ("AmMax") and an exclusive worldwide license from Amgen for the...

at 07:05
AstraZeneca today announced that IMFINZI® (durvalumab) has been approved in the US as a 1st-line treatment for adult patients with extensive-stage small cell lung cancer (ES-SCLC) in combination with standard-of-care (SoC) chemotherapies, etoposide...

at 07:05
ElevateBio, LLC, a Cambridge-based creator and operator of a portfolio of innovative cell and gene therapy companies, today announced it has closed a $170-million Series B financing that will support and accelerate the company's next phase of growth....



News published on 27 february 2020 at 08:15 and distributed by: